Switching children from artisanal CBD to Epidiolex
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study looks at switching children with Dravet or Lennox Gastaut syndrome from artisanal CBD products to a standardized FDA-approved CBD medication called Epidiolex, to see if it works as well or better for seizure control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Children aged 2 to 18 years old with Dravet or Lennox Gastaut syndrome.
- Must be currently taking a stable dose of artisanal CBD (with a high CBD to THC ratio) for at least 3 months.
- Must also be taking at least one other seizure medication, stable for at least 28 days.
- If using a vagal nerve stimulator or ketogenic diet, the settings must be stable.
- Must be willing to keep a seizure diary and avoid other cannabis products or alcohol during the study.
- Cannot have used Epidiolex before, or be pregnant, breastfeeding, or have certain liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new CBD patch placed on the skin to see if it can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome. The patch delivers CBD slowly over time, and the goal is to help control seizures that are not well managed by current medications.
This trial tests a new type of brain stimulation (adaptive deep brain stimulation) that adjusts in real time to stop seizures in children with Lennox-Gastaut syndrome. It's for children who haven't gotten enough help from medications and have frequent drop seizures.
This early-phase trial tests an experimental medicine called RC001 in children with Dravet syndrome caused by SCN1A gene changes. The goal is to see if RC001 is safe and how the body processes it, with the hope of reducing seizures.
This study tests a gradual dose increase of CBD oil (Epidiolex) to see if it helps reduce seizures in adults with Lennox-Gastaut syndrome. It's for people who haven't tried CBD before or haven't used it in at least 3 months.
This trial tests if adding cannabidiol (CBD) to your child's current seizure medicines can reduce seizures. It uses a personalized approach to see if CBD works for each child.
This study tests whether giving a medicine called Epidiolex (a purified form of CBD) to babies with Sturge-Weber syndrome before they have seizures can prevent or delay the start of seizures and improve their development.
Hear when a new Lennox Gastaut Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.